Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 28

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 28
---
 long-term equity awards. We also offer comprehensive employee
benefits, which vary by country and region, such as life, disability, and health insurance, health savings and flexible spending accounts,
paid time off, and a 401(k) plan. It is our expressed intent to be an employer of choice in our industry by providing market-competitive
compensation and benefits packages.

Health, Safety, and
Wellness

The health, safety, and wellness
of our employees is a priority in which we have always invested and will continue to do so. We provide our employees and their families
with access to a variety of innovative, flexible, and convenient health and wellness programs. Program benefits are intended to provide
protection and security, so employees can have peace of mind concerning events that may require time away from work or that may impact
their financial well-being.

Training and Development

We believe in encouraging employees
in becoming lifelong learners by providing ongoing learning, training and leadership opportunities. We provide our employees with a tuition
reimbursement program, and in certain instances, onsite training programs. While we strive to provide real-time recognition of employee
performance, we have a formal annual review process not only to determine pay and equity adjustments tied to individual contributions,
but to identify areas where training and development may be needed.

Company Information

We were incorporated in Delaware
in January 2006 as Bywater Resources, Inc. In September 2007, we closed a merger transaction with Transdel Pharmaceuticals Holdings,
Inc. and changed our name to Transdel Pharmaceuticals, Inc. As part of a corporate re-organization that was led by our Chief Executive
Officer, Mark L. Baum and our Chief Financial Officer, Andrew R. Boll, we changed our name to Imprimis Pharmaceuticals, Inc. in February
2012. Then to align with a shift in our corporate strategy that included the expansion into branded ophthalmic products and product candidates,
we changed the name of our company to Harrow Health, Inc. in December 2018 and then to Harrow, Inc. in September 2023.

Our corporate headquarters are
located at 1A Burton Hills Blvd., Suite 200, Nashville, Tennessee, 37215, and our telephone number at such office is (615) 733-4730.

We file reports with the Securities
and Exchange Commission (“SEC”), including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports
from time to time. We are an electronic